Abstract
Immunological enhancement of heterotopic cardiac allografts in rats was achieved by pretreatment of recipients with donor spleen and bone marrow cells (active enhancement) and by administration of noncytotoxic alloantiserum obtained from recipient strain rats immunized against donor spleen or bone marrow cells (passive enhancement). The prolongation of survival, though statistically significant, was not as great as the indefinite survival of renal allografts reported by others using similar treatment protocols. Specific and dose-dependent inhibition of recipient-donor mixed lymphocyte reactions was caused by alloantisera which graft survival in vivo. Mixed lymphocyte reactions also indicated that in actively enhanced recipients peripheral inhibition of rejection rather than central tolerance was the mechanism responsible for prolongation of allograft survival.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
